Tilray Brands (NASDAQ:TLRY) Trading 1.8% Higher - Here's Why

Key Points

• Tilray Brands shares rose 1.8% during Wednesday trading, briefly reaching $5.69 before closing near $5.55, with volume below its average session level.
• Recent business updates were mostly positive, including a BrewDog summer marketing campaign in the U.K. and Tilray Medical’s appearance at Cannabis Europa London 2026, both of which support brand visibility and international medical-cannabis positioning.
• The stock remains heavily tied to regulation and weak fundamentals: commentary says TLRY still needs U.S. marijuana rescheduling or another major catalyst to sustain gains, while the company also posted a quarterly EPS miss and its stock is still far below recent moving averages.

Tilray Brands, Inc. (NASDAQ:TLRY - Get Free Report) traded up 1.8% during mid-day trading on Wednesday . The stock traded as high as $5.69 and last traded at $5.55. 3,288,637 shares traded hands during trading, a decline of 25% from the average session volume of 4,411,596 shares. The stock had previously closed at $5.45.

Tilray Brands News Roundup

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray’s BrewDog brand launched a broad summer “Underdog” marketing campaign in the U.K., including retail promotions, bar activations, digital media, a “Win a Year of Beer” contest, and watch parties, which could help support beverage sales and brand visibility. Article Title
• Positive Sentiment: Tilray Medical highlighted its presence at Cannabis Europa London 2026, reinforcing the company’s international medical-cannabis expertise and its focus on patient access and regulatory discussions. Article Title
• Neutral Sentiment: Several commentary pieces note that Tilray’s fundamentals have improved somewhat, but the stock still hinges heavily on potential U.S. marijuana rescheduling or other federal regulatory changes to drive a sustained move higher. Article Title
• Neutral Sentiment: Another market commentary says Tilray looks positioned for a breakout only if a key catalyst materializes, again emphasizing that regulation rather than operating momentum is likely to matter most for the stock. Article Title
• Negative Sentiment: Recent coverage also stresses that TLRY has fallen sharply this year and remains near multi-month lows, reflecting ongoing investor concern about the company’s weak share performance and limited near-term catalysts. Article Title

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. TD Cowen dropped their price objective on Tilray Brands from $10.00 to $7.00 and set a "buy" rating for the company in a report on Monday, March 30th. Wall Street Zen raised Tilray Brands from a "sell" rating to a "hold" rating in a report on Saturday, March 21st. Roth Mkm raised Tilray Brands from a "neutral" rating to a "buy" rating and set a $10.00 price objective for the company in a report on Thursday, April 2nd. Zacks Research raised Tilray Brands from a "strong sell" rating to a "hold" rating in a report on Wednesday, February 11th. Finally, Weiss Ratings cut Tilray Brands from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, May 13th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tilray Brands presently has a consensus rating of "Hold" and a consensus target price of $11.50.

Tilray Brands Trading Up 1.8%

The company has a current ratio of 2.79, a quick ratio of 1.66 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $646.85 million, a P/E ratio of -0.41 and a beta of 1.94. The business has a 50 day moving average price of $6.28 and a 200 day moving average price of $8.02.

Tilray Brands (NASDAQ:TLRY - Get Free Report) last announced its quarterly earnings results on Wednesday, April 1st. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.10). The company had revenue of $206.73 million during the quarter, compared to the consensus estimate of $201.35 million. Tilray Brands had a negative net margin of 156.51% and a negative return on equity of 3.31%. During the same period last year, the company earned ($0.87) earnings per share. Analysts anticipate that Tilray Brands, Inc. will post -0.58 EPS for the current year.

Insider Buying and Selling

In other Tilray Brands news, Director David G. Hopkinson sold 33,556 shares of the business's stock in a transaction dated Tuesday, April 21st. The stock was sold at an average price of $6.94, for a total value of $232,878.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.84% of the company's stock.

Institutional Trading of Tilray Brands

Several hedge funds have recently bought and sold shares of the stock. Hilton Head Capital Partners LLC acquired a new position in Tilray Brands in the 4th quarter worth $38,000. Essential Partners LLC boosted its stake in Tilray Brands by 110,137.5% in the 1st quarter. Essential Partners LLC now owns 8,819 shares of the company's stock worth $57,000 after purchasing an additional 8,811 shares during the period. Engineers Gate Manager LP acquired a new position in Tilray Brands in the 4th quarter worth $126,000. Oppenheimer & Co. Inc. acquired a new position in Tilray Brands in the 3rd quarter worth $25,000. Finally, R Squared Ltd bought a new position in shares of Tilray Brands during the 1st quarter worth approximately $94,000. 9.35% of the stock is currently owned by institutional investors and hedge funds.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray's product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.